Access to Affordable Life-Saving Medications
Health and Human Services Directs Clinics to Offer Discounted Insulin and Epinephrine
What it does
Health and Human Services must require federally qualified health centers receiving future grants to sell insulin and injectable epinephrine at their discounted 340B purchase prices to low-income patients.
Real-world impact
- Makes insulin and epinephrine cheaper at community health centers for low-income patients.
- Requires clinics to adopt practices or risk losing future federal grants.
- Reduces out-of-pocket costs for uninsured people and those with high deductibles.
Topics
Summary
This order directs the Department of Health and Human Services to require federally qualified health centers (community clinics that receive federal funding) to make insulin and injectable epinephrine available to low-income patients at the same discounted price the clinic paid under the federal 340B drug discount program, plus a small administration fee.
It applies to people who face high cost-sharing, high unmet deductibles, or who lack health insurance. The change aims to help people who struggle to afford these life-saving medicines.
Questions, answered
Ask questions about this executive order and its implications. Try:
- “What agencies are affected by this order?”
- “How does this order change existing policy?”
- “What are the practical implications of this order?”